ALSO NOTED: Encysive shares climb as trial resumes; Donors support bird flu fight; and much more...

> Shares of Encysive were climbing this morning on the news that the FDA had cleared its researchers to resume a trial on TBC3711, the company's next-generation endothelin receptor antagonist. Report

> International donors have pledged $476 million in additional support to fight the spread of bird flu. Report

> Innovive Pharmaceuticals has acquired exclusive North American rights to develop and commercialize Tamibarotene, a synthetic retinoid for the treatment of acute promyelocytic leukemia, a type of acute myeloid leukemia. Release

> DOV Pharmaceutical announced today that the license agreement with Merck for DOV 21,947 and DOV 216,303, has been terminated by the parties. DOV regains all rights to the compounds. Release

> Canada's Millenium Biologix has laid off 20 staffers as it looks for new financing. Release

> Chutes & Ladders: Novacea CEO Bradford Goodwin has resigned for personal reasons. Report

> Gilead Sciences has been subpoenaed by federal prosecutors investigating its marketing efforts behind three HIV therapies. Report

> Crucell has announced a new $20 million contract for its Quinvaxem vaccine. Report

> Actelion moved on its earlier announced plans to acquire CoTherix by launching a $13.50 a share tender offer. Report

> Economic development: Malaysia plays catch-up for biotech business. Report

And Finally… The NIH has been steadily ratcheting down the amount of money that is available to researchers whose studies are considered risky. Article (WSJ sub. req.)